Kodiak Sciences Inc. (KOD) Stock Analysis and Metrics

Kodiak Sciences

NASDAQ: KOD

$41.36 ▲ +0.34 (+0.83%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap2.56 Bn

P/E-2.14

Div. Yield0.00

Add ratio to table…

About

Kodiak Sciences Inc. develops retinal therapeutics using its proprietary Antibody Biopolymer Conjugate (ABC) platform to address unmet needs in retinal diseases. The company focuses on creating next-generation treatments for conditions such as diabetic retinopathy, retinal vein occlusion, wet age-related macular degeneration, and macular edema secondary to inflammation. Its pipeline includes clinical-stage product candidates designed for extended durability and improved efficacy through sustained drug delivery in ocular tissues.

Kodiak Sciences Inc. generates revenue primarily through the development and potential commercialization of its investigational medicines, with no current product sales as all candidates remain in clinical stages. The company's lead asset, tarcocimab tedromer (Zenkuda or KSI-301), is an anti-VEGF therapy built on the ABC platform, alongside KSI-501, an anti-IL-6 VEGF-trap bispecific, and KSI-101, a high-strength bispecific targeting IL-6 and VEGF for macular edema secondary to inflammation. Revenue generation is anticipated upon regulatory approval and commercial launch of these therapeutics in major markets such as the United States and Europe.

Kodiak Sciences Inc. operates through the following segments:

• Tarcocimab tedromer (Zenkuda/KSI-301): This segment encompasses the development of an anti-VEGF therapy built on the ABC platform, designed for extended ocular half-life and durable efficacy in retinal vascular diseases. Zenkuda has demonstrated positive results in Phase 3 trials for diabetic retinopathy (GLOW1, GLOW2), retinal vein occlusion (BEACON), and wet AMD (DAYLIGHT), with the ongoing DAYBREAK study evaluating flexible dosing from monthly to every six months. The enhanced 50 mg/mL formulation contains both conjugated and unconjugated antibody to balance immediacy and durability.

• KSI-501: This segment focuses on an anti-IL-6, VEGF-trap bispecific therapy built on the ABC platform, targeting retinal vascular diseases by addressing both VEGF and inflammatory pathways. KSI-501 is being evaluated in the Phase 3 DAYBREAK study for wet AMD, using the same enhanced 50 mg/mL formulation as Zenkuda to support individualized dosing based on disease activity. Preclinical data show KSI-501 inhibits VEGF and IL-6, normalizes the blood retinal barrier, and may offer disease-modifying potential beyond current anti-VEGF monotherapies.

• KSI-101: This segment develops a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF for macular edema secondary to inflammation (MESI), a condition driven by blood retinal barrier disruption and inflammation. KSI-101 is being evaluated in the Phase 3 PEAK and PINNACLE studies, which are actively enrolling patients at 5 mg and 10 mg dose levels versus sham, with topline data expected in 4Q 2026 and 2Q 2027. The APEX Phase 1b study demonstrated meaningful visual and anatomical gains in both diabetic macular edema and MESI populations, supporting its potential as a unifying therapy for inflammation-driven retinal fluid.

Kodiak Sciences Inc. operates in a competitive retinal therapeutics landscape dominated by established anti-VEGF agents such as Eylea, Avastin, Lucentis, and Vabysmo, which are frequently used for diabetic retinopathy, retinal vein occlusion, and wet age-related macular degeneration. The company differentiates itself through its ABC platform, enabling prolonged drug retention in ocular tissues and less frequent dosing, aiming to reduce treatment burden while maintaining or improving visual and anatomical outcomes. Its focus on bispecific and multi-targeted approaches, such as IL-6 and VEGF dual inhibition, positions it to address limitations of current monotherapy standards by targeting broader disease biology.

Kodiak Sciences Inc. serves patients suffering from retinal diseases, including those with diabetic retinopathy, retinal vein occlusion, wet age-related macular degeneration, and macular edema secondary to inflammation, with therapies administered by retina specialists in clinical settings such as ophthalmology clinics and retinal care centers. The company's product candidates are intended for use by adult patients requiring intravitreal injections to manage vision-threatening retinal conditions, with no specific named customers disclosed in the filing as all therapeutics remain investigational.

Investment Thesis

▲ Bull case

The positive topline results from the GLOW2 study showed that 62.5% of patients achieved a two step improvement on the diabetic retinopathy severity scale compared with 3.3% in the sham arm with a p value less than 0.0001 indicating strong statistical significance and confirming the efficacy of Zenkuda across a broader patient population that includes proliferative diabetic retinopathy and mild diabetic macular edema. This outcome builds on the earlier GLOW1 study where 41.1% of Zenkuda treated patients achieved the same endpoint versus 1.4% in sham demonstrating a consistent dose response and reinforcing the durability of the antibody biopolymer conjugate platform. The combined data package positions Zenkuda for a multi indication biologics license application that could cover diabetic retinopathy retinal vein occlusion and wet age related macular degeneration targeting a market estimated at fifteen billion dollars. Management has signaled an intention to accelerate the BLA submission timeline with the expectation that topline data from the DAYBREAK study in wet AMD will be available in the Q3 FY26 providing a near term catalyst for regulatory progress.
KSI 501 combines VEGF trap and IL 6 inhibition in a bispecific format built on the same antibody biopolymer conjugate platform aiming to deliver both immediate efficacy and extended durability while addressing disease biology beyond VEGF alone and preclinical data suggest it may normalize the blood retinal barrier and act as a disease modifying therapy for retinal vascular diseases. KSI 101 targets macular edema secondary to inflammation with a bispecific protein that has shown rapid visual and anatomical gains in Phase 1b studies including a mean BCVA increase of 17.8 letters and sustained retinal dryness in a tertiary care cohort in Taiwan supporting its applicability across diverse etiologies and geographic regions. The company is advancing KSI 101 into two Phase 3 studies PEAK and PINNACLE with topline readouts expected in the Q4 FY26 and the Q2 FY27 respectively which could unlock a new market segment separate from the established anti VEGF arena. Parallel discovery efforts are generating additional bispecific candidates such as KSI 102 and KSI 103 that target complementary inflammatory pathways and duet programs built on the ABCD platform are exploring combinations for glaucoma and geographic atrophy further diversifying the pipeline beyond the core VEGF focused assets.
At the end of 2025 Kodiak reported cash and cash equivalents of 209.9 million dollars and following the upsized public offering in December 2025 that yielded net proceeds of approximately 173 million dollars the company stated that its current cash position will support operations into 2027 providing a sufficient runway to await multiple clinical readouts without immediate need for additional financing. The offering was executed at a price of 23.00 dollars per share and included the full exercise of the underwriters option adding 1.04 million shares which demonstrates investor confidence in the near term milestones and reduces the risk of a funding gap during the pivotal period leading up to potential BLA submissions. While the company continues to incur net losses the cash balance coupled with the non dilutive nature of the shelf registration allows flexibility to access capital on favorable terms should future milestones be met. This financial backdrop contrasts with many pre commercial biotech peers that rely on frequent dilutive rounds and gives Kodiak a relatively stable platform to execute its development plan.
Beyond its therapeutic programs Kodiak has made substantial progress with its digital health and artificial intelligence capabilities through the VETi platform which is developing an AI powered wearable headset with applications in retina care alongside opportunities in identity security and cognitive science representing a strategic shift toward a broader vision sciences company that could generate ancillary revenue streams and increase the overall valuation multiple. The integration of proprietary therapeutics with next generation vision technologies may create synergies that improve patient engagement adherence to treatment regimens and provide real world data to support regulatory submissions and differentiate Kodiak from pure play biotech firms. Early hardware software and machine learning advancements indicate that the platform is moving from concept toward prototype stage and could become a meaningful contributor to long term growth if commercialized successfully. This diversification effort is not heavily highlighted in recent news releases but constitutes a structural shift that may reduce reliance on drug approval alone and provide downside protection to the core pipeline.

The positive topline results from the GLOW2 study showed that 62.5% of patients achieved a two step improvement on the diabetic retinopathy severity scale compared with 3.3% in the sham arm with a p value less than 0.0001 indicating strong statistical significance and confirming the efficacy of Zenkuda across a broader patient population that includes proliferative diabetic retinopathy and mild diabetic macular edema. This outcome builds on the earlier GLOW1 study where 41.1% of Zenkuda treated patients achieved the same endpoint versus 1.4% in sham demonstrating a consistent dose response and reinforcing the durability of the antibody biopolymer conjugate platform. The combined data package positions Zenkuda for a multi indication biologics license application that could cover diabetic retinopathy retinal vein occlusion and wet age related macular degeneration targeting a market estimated at fifteen billion dollars. Management has signaled an intention to accelerate the BLA submission timeline with the expectation that topline data from the DAYBREAK study in wet AMD will be available in the Q3 FY26 providing a near term catalyst for regulatory progress.
KSI 501 combines VEGF trap and IL 6 inhibition in a bispecific format built on the same antibody biopolymer conjugate platform aiming to deliver both immediate efficacy and extended durability while addressing disease biology beyond VEGF alone and preclinical data suggest it may normalize the blood retinal barrier and act as a disease modifying therapy for retinal vascular diseases. KSI 101 targets macular edema secondary to inflammation with a bispecific protein that has shown rapid visual and anatomical gains in Phase 1b studies including a mean BCVA increase of 17.8 letters and sustained retinal dryness in a tertiary care cohort in Taiwan supporting its applicability across diverse etiologies and geographic regions. The company is advancing KSI 101 into two Phase 3 studies PEAK and PINNACLE with topline readouts expected in the Q4 FY26 and the Q2 FY27 respectively which could unlock a new market segment separate from the established anti VEGF arena. Parallel discovery efforts are generating additional bispecific candidates such as KSI 102 and KSI 103 that target complementary inflammatory pathways and duet programs built on the ABCD platform are exploring combinations for glaucoma and geographic atrophy further diversifying the pipeline beyond the core VEGF focused assets.
At the end of 2025 Kodiak reported cash and cash equivalents of 209.9 million dollars and following the upsized public offering in December 2025 that yielded net proceeds of approximately 173 million dollars the company stated that its current cash position will support operations into 2027 providing a sufficient runway to await multiple clinical readouts without immediate need for additional financing. The offering was executed at a price of 23.00 dollars per share and included the full exercise of the underwriters option adding 1.04 million shares which demonstrates investor confidence in the near term milestones and reduces the risk of a funding gap during the pivotal period leading up to potential BLA submissions. While the company continues to incur net losses the cash balance coupled with the non dilutive nature of the shelf registration allows flexibility to access capital on favorable terms should future milestones be met. This financial backdrop contrasts with many pre commercial biotech peers that rely on frequent dilutive rounds and gives Kodiak a relatively stable platform to execute its development plan.
Beyond its therapeutic programs Kodiak has made substantial progress with its digital health and artificial intelligence capabilities through the VETi platform which is developing an AI powered wearable headset with applications in retina care alongside opportunities in identity security and cognitive science representing a strategic shift toward a broader vision sciences company that could generate ancillary revenue streams and increase the overall valuation multiple. The integration of proprietary therapeutics with next generation vision technologies may create synergies that improve patient engagement adherence to treatment regimens and provide real world data to support regulatory submissions and differentiate Kodiak from pure play biotech firms. Early hardware software and machine learning advancements indicate that the platform is moving from concept toward prototype stage and could become a meaningful contributor to long term growth if commercialized successfully. This diversification effort is not heavily highlighted in recent news releases but constitutes a structural shift that may reduce reliance on drug approval alone and provide downside protection to the core pipeline.

▼ Bear case

The company's near term value is heavily dependent on the success of upcoming Phase 3 readouts including the DAYBREAK study in wet AMD expected in the Q3 FY26 and the PEAK and PINNACLE studies for KSI 101 expected in the Q4 FY26 and Q2 FY27 respectively and any failure to meet primary endpoints or demonstrate non inferiority could severely impair the BLA ready profile of Zenkuda and delay or derail potential regulatory submissions for both Zenkuda and KSI 501. Although GLOW1 and GLOW2 showed superiority over sham the FDA may still require additional confirmatory evidence or a head to head comparison against approved anti VEGF agents such as aflibercept before granting approval especially for indications beyond diabetic retinopathy. The platform's novelty means that regulatory agencies may request longer term safety data or additional studies to assess immunogenicity and durability risks that are not yet fully characterized in the existing trial set. A negative outcome in any of the pivotal studies would not only erase the near term upside but could also raise concerns about the translational validity of the antibody biopolymer conjugate technology across different disease areas.
Even if Zenkuda gains approval it will enter a highly competitive anti VEGF market dominated by established agents such as aflibercept faricizumab and brolucizumab that benefit from strong physician familiarity entrenched reimbursement pathways and robust manufacturing scale which could limit uptake despite its purported durability advantages. The convenience of less frequent dosing may be offset by clinician inertia and the need for real world evidence to confirm that extended intervals do not compromise visual outcomes in diverse practice settings. Moreover the emergence of newer therapeutic modalities such as gene therapy port delivery systems and faricizumab's dual angiopoeitin VEGF inhibition could further erode the addressable market for a molecule that primarily targets VEGF alone unless KSI 501 or KSI 101 demonstrate clear incremental benefit beyond VEGF inhibition. The company's reliance on a single platform for multiple indications increases the risk that a platform wide safety or manufacturing issue could affect all pipeline assets simultaneously.
Despite the recent cash influx Kodiak continues to burn cash at a high rate with a net loss of 229.9 million dollars for the full year 2025 and a quarterly loss of 56.7 million dollars in the fourth quarter reflecting substantial investment in clinical trials personnel and stock based compensation which translates to a significant quarterly cash outflow that could erode the cash balance faster than anticipated if trial expenses increase or enrollment delays occur. The company has already diluted shareholders through multiple equity offerings including the December 2025 upsized offering that issued approximately eight million shares and any future financing needs may result in further dilution especially if clinical milestones are missed and investors demand higher risk premiums. Maintaining sufficient liquidity to fund operations through 2027 assumes that spending will remain at current levels which may be optimistic given the typical cost inflation associated with late stage Phase 3 studies and the potential need for additional manufacturing scale up activities prior to commercial launch. A scenario where cash runs out before key data readouts could force a distressed financing or a strategic transaction at unfavorable terms.
The broader biotechnology sector has faced heightened scrutiny from investors regarding valuation and profitability and a shift toward risk off sentiment could make it more difficult for pre commercial companies to access capital on favorable terms even if they achieve clinical success. Kodiak lacks any commercial sales or marketing infrastructure and will need to build or partner for distribution manufacturing and reimbursement negotiations which adds execution risk and may delay revenue generation post approval. Additionally the company's focus on retinal diseases means that its performance is tied to the prevalence and diagnosis rates of conditions such as diabetic retinopathy and wet AMD which could be influenced by changes in diabetes management patterns screening guidelines or healthcare policy shifts that affect patient access to intravitreal therapies. Macroeconomic headwinds such as rising interest rates or a recession could reduce discretionary spending on elective procedures and increase pressure on healthcare budgets further limiting the potential market size and pricing power for new entrants in the ophthalmology space.

The company's near term value is heavily dependent on the success of upcoming Phase 3 readouts including the DAYBREAK study in wet AMD expected in the Q3 FY26 and the PEAK and PINNACLE studies for KSI 101 expected in the Q4 FY26 and Q2 FY27 respectively and any failure to meet primary endpoints or demonstrate non inferiority could severely impair the BLA ready profile of Zenkuda and delay or derail potential regulatory submissions for both Zenkuda and KSI 501. Although GLOW1 and GLOW2 showed superiority over sham the FDA may still require additional confirmatory evidence or a head to head comparison against approved anti VEGF agents such as aflibercept before granting approval especially for indications beyond diabetic retinopathy. The platform's novelty means that regulatory agencies may request longer term safety data or additional studies to assess immunogenicity and durability risks that are not yet fully characterized in the existing trial set. A negative outcome in any of the pivotal studies would not only erase the near term upside but could also raise concerns about the translational validity of the antibody biopolymer conjugate technology across different disease areas.
Even if Zenkuda gains approval it will enter a highly competitive anti VEGF market dominated by established agents such as aflibercept faricizumab and brolucizumab that benefit from strong physician familiarity entrenched reimbursement pathways and robust manufacturing scale which could limit uptake despite its purported durability advantages. The convenience of less frequent dosing may be offset by clinician inertia and the need for real world evidence to confirm that extended intervals do not compromise visual outcomes in diverse practice settings. Moreover the emergence of newer therapeutic modalities such as gene therapy port delivery systems and faricizumab's dual angiopoeitin VEGF inhibition could further erode the addressable market for a molecule that primarily targets VEGF alone unless KSI 501 or KSI 101 demonstrate clear incremental benefit beyond VEGF inhibition. The company's reliance on a single platform for multiple indications increases the risk that a platform wide safety or manufacturing issue could affect all pipeline assets simultaneously.
Despite the recent cash influx Kodiak continues to burn cash at a high rate with a net loss of 229.9 million dollars for the full year 2025 and a quarterly loss of 56.7 million dollars in the fourth quarter reflecting substantial investment in clinical trials personnel and stock based compensation which translates to a significant quarterly cash outflow that could erode the cash balance faster than anticipated if trial expenses increase or enrollment delays occur. The company has already diluted shareholders through multiple equity offerings including the December 2025 upsized offering that issued approximately eight million shares and any future financing needs may result in further dilution especially if clinical milestones are missed and investors demand higher risk premiums. Maintaining sufficient liquidity to fund operations through 2027 assumes that spending will remain at current levels which may be optimistic given the typical cost inflation associated with late stage Phase 3 studies and the potential need for additional manufacturing scale up activities prior to commercial launch. A scenario where cash runs out before key data readouts could force a distressed financing or a strategic transaction at unfavorable terms.
The broader biotechnology sector has faced heightened scrutiny from investors regarding valuation and profitability and a shift toward risk off sentiment could make it more difficult for pre commercial companies to access capital on favorable terms even if they achieve clinical success. Kodiak lacks any commercial sales or marketing infrastructure and will need to build or partner for distribution manufacturing and reimbursement negotiations which adds execution risk and may delay revenue generation post approval. Additionally the company's focus on retinal diseases means that its performance is tied to the prevalence and diagnosis rates of conditions such as diabetic retinopathy and wet AMD which could be influenced by changes in diabetes management patterns screening guidelines or healthcare policy shifts that affect patient access to intravitreal therapies. Macroeconomic headwinds such as rising interest rates or a recession could reduce discretionary spending on elective procedures and increase pressure on healthcare budgets further limiting the potential market size and pricing power for new entrants in the ophthalmology space.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password